GlaxoSmithKline: Positive Data For Bepirovirsen From B-Clear Phase Iib Trial Presented At American Association For The Study Of Liver Diseases' Meeting With Simultaneous Publication In The New England Journal Of Medicine
November 09, 2022
November 09, 2022
LONDON, England, Nov. 9 (TNSjou) -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release:
* * *
- Phase III trial evaluating bepirovirsen to start in H1 2023
- Phase II trials ongoing to explore potential sequential treatment options with the aim of increasing functional cure rate
* * *
GSK plc (LSE/NYSE: GSK) today announced the publication of positive end of study results from the B-Clear phase IIb tria . . .
* * *
- Phase III trial evaluating bepirovirsen to start in H1 2023
- Phase II trials ongoing to explore potential sequential treatment options with the aim of increasing functional cure rate
* * *
GSK plc (LSE/NYSE: GSK) today announced the publication of positive end of study results from the B-Clear phase IIb tria . . .